Transpire Bio Receives FDA Orphan Drug Designation for Inhaled Therapies Targeting IPF and Glioblastoma
Key Insights
Transpire Bio (search) secured FDA orphan drug designation for TRB-ILD1 (search), an inhaled phosphodiesterase-4 (search) inhibitor for treating idiopathic pulmonary fibrosis (search).
The company also received orphan drug designation for TRB-ONC1 (search), a novel synthetic inhaled cannabidiol formulation targeting glioblastoma (search) brain cancer.
Both designations provide regulatory incentives including tax credits, fee exemptions, and potential seven-year market exclusivity upon approval.
Transpire Bio (search), a clinical-stage biopharmaceutical company specializing in inhaled therapeutics, announced that the U.S. FDA has granted orphan drug designation for two investigational treatments targeting rare diseases with significant unmet medical needs. The designations cover TRB-ILD1 (search) for idiopathic pulmonary fibrosis (search) and TRB-ONC1 (search) for glioblastoma (search), marking important regulatory milestones for the Florida-based company's inhaled drug delivery platform.
Novel Inhaled Approaches for Rare Diseases
TRB-ILD1 (search) represents an inhaled phosphodiesterase-4 (search) (PDE4) inhibitor formulation designed to treat idiopathic pulmonary fibrosis (search) (IPF), a progressive lung disease characterized by scarring of lung tissue. The inhaled delivery approach aims to provide targeted therapy directly to the lungs while potentially reducing systemic side effects associated with oral PDE4 inhibitors.
TRB-ONC1 (search) introduces a novel synthetic inhaled cannabidiol (CBD) formulation for treating glioblastoma (search) (GBM), described as "an aggressive brain cancer with limited effective therapies." This represents an innovative approach to delivering cannabidiol therapy through inhalation for a brain cancer indication, potentially offering a new treatment modality for patients with this devastating disease.
Regulatory Benefits and Development Incentives
The FDA's orphan drug designation program provides substantial incentives for developing therapies for rare diseases affecting fewer than 200,000 people in the United States. Companies receiving this designation benefit from tax credits for qualified clinical trials, exemption from user fees, and potential seven-year market exclusivity following regulatory approval.
"Receiving orphan drug designation for both TRB-ILD1 (search) and TRB-ONC1 (search) marks an important milestone in our efforts to bring transformative, inhaled treatment options to people living with rare diseases like idiopathic pulmonary fibrosis (search) and glioblastoma (search)," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio (search).
Expanding Pipeline of Inhaled Therapeutics
Transpire Bio (search) has positioned itself as an integrated, revenue-generating biopharmaceutical company with expertise in inhaled drug delivery systems. The company has developed multiple proprietary inhalation technology platforms, including dry powder inhalers and soft-mist inhalers, to support its therapeutic development programs.
Beyond the two orphan-designated products, Transpire Bio (search) is building a comprehensive pipeline of inhaled medicines for IPF, with three assets currently in development for this indication. The company's broader therapeutic focus extends to pulmonary arterial hypertension (search), diabetes (search), obesity (search), Parkinson's disease psychosis (search), and glioblastoma (search).
Mark Lepore, MD, Chief Medical Officer of Transpire Bio (search), emphasized the company's commitment to addressing unmet medical needs: "Our team in South Florida has extensive expertise in developing inhaled medicines, and we are dedicated to finding new treatment options to help patients living with rare diseases live better lives."
Strategic Focus on Inhaled Drug Delivery
The orphan drug designations validate Transpire Bio (search)'s strategic approach of leveraging inhaled drug delivery to address serious diseases where therapeutic options are significantly lacking. By focusing on inhalation as a delivery method, the company aims to improve patient access to important therapies while potentially enhancing therapeutic efficacy and reducing systemic toxicity.
The company's headquarters in Sunrise, Florida, serves as the base for its integrated operations spanning drug development, manufacturing capabilities, and clinical advancement of its inhaled therapeutic portfolio.